Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
Status:
Completed
Trial end date:
2020-07-24
Target enrollment:
Participant gender:
Summary
The proposed initial trial is a Phase I, open label study to evaluate the safety and explore
efficacy of MG005 in combination with sorafenib in patients with solid tumor. The eligible
patients will receive 200 mg of sorafenib with 3 pre-defined dose levels of GW5074, escalated
from 750 mg to 1500 mg (daily dose), to determine the Maximum Tolerated Dose (MTD) and dose
limiting toxicities (DLT) (if any) at Phase I stage.